Abiomed to present brand-new data from PROTECT II study in PCI in SCAI meeting Abiomed Inc.

Minogue, Chairman, President and CEO, Abiomed. We are excited to provide the PROTECT II data to these SCAI members who are devoted to enhancing the typical of care for individuals in the cath lab. SCAI members represent 4,000 adult and congenital interventional cardiologists. Concentrate areas for SCAI include establishing guidelines and requirements for all aspects of cardiac catheterization and angiography, training, credentialing, safety and quality assurance for cardiovascular methods.. Abiomed to present brand-new data from PROTECT II study in PCI in SCAI meeting Abiomed Inc. , a leading provider of breakthrough center support technologies, announced that brand-new data from the PROTECT II research will be shown by William O’Neill today, M.D., executive dean for scientific affairs at the University of Miami Miller College of Medication, and principal investigator for the PROTECT II research, during the late-breaking scientific trials program at the Society for Cardiovascular Angiography and Interventions 2011 Scientific Periods in Baltimore, Maryland.Produced by Professor. Louis co-workers and Dubeau at Keck College of Medicine, University of Southern California, USA, this fresh model helps experts understand what's behind the effect of the menstrual period on the risk of breast and ovarian tumor. Related StoriesCornell biomedical engineers develop 'super natural killer cells' to destroy cancers cells in lymph nodesMeat-rich diet may increase kidney cancer riskStudy displays uncommon HER2 missense mutations do not spread breasts cancer on their ownThe model uses genetically engineered mice that carry mutations in the same as the human being BRCA1 gene, not merely in tissues corresponding to those at increased risk of cancer in human BRCA1 mutation carriers, but also in the organs that control the menstrual cycle: the ovaries and the pituitary gland.